Clinical Trials Logo

Clinical Trial Summary

Sleep at altitude is often poor. The purpose of this study is to evaluate the effects of a single dose of the opioid antagonist, naltrexone, on sleep quality and periodic breathing after rapid ascent to ~3800m altitude.


Clinical Trial Description

Sleep at high altitude is notoriously poor due to a combination of the unusual sleep environment and hypoxia during sleep. Many people develop what is called periodic breathing (PB) during sleep. PB may improve overall mean nocturnal oxygen saturation (SpO2) although this is not entirely clear. Simultaneously, PB may further disturb sleep at altitude and has been associated with nighttime arousals from sleep. Medications that may decrease the amount of PB might improve sleep quality. The FDA approved drug, naltrexone, is a specific antagonist to the brain opioid receptors. It is a non-addicting drug which has never been studied at altitude. Clinical Relationships: Sleep disordered breathing is a very common disorder throughout the population, but it worsens with increasing age and BMI. At the same time, many in our Veteran population live in the local mountains and undoubtedly develop PB during sleep in addition to having obstructive sleep apnea. Objectives: The purpose to this study is to evaluate the effects of a single dose of naltrexone on PB and oxygen saturation during sleep at altitude in healthy young participants. The additional purpose will be to assess the subject-perceived sleep quality after the use of naltrexone vs. placebo. Research Design: A prospective, randomized, double-blind, crossover study. Methodology: We plan recruit up to 30 healthy study subjects with no history of sleep disordered breathing. Potential participants will be screened to ensure inclusion and exclusion criteria are met. A baseline low altitude sleep study will be preformed at home. No medication will be given before this baseline sleep study. The sleep study will be similar to the home sleep studies routinely used by the VA Loma Linda Healthcare System's Sleep Center. Participants will be transported for High Altitude Trip 1 to the Barcroft Laboratory at the White Mountain Research Center (WMRC) at 3810 m altitude. At WMRC they will have a sleep study performed, similar to the baseline sleep study, after taking either a single dose of naltrexone or matching placebo. After an appropriate washout period (at least 5 half-lives) subjects will again be studied (High Altitude Trip 2) taking the alternate medication (naltrexone/placebo) to the one used in the first study. Order of placebo vs. naltrexone will be randomized. Prior to sleep the subject will fill out questionnaires detailing how sleepy they are. On the morning following each sleep study, subjects will fill out a short questionnaire assessing the quality of their sleep. Impact/Significance: Improved knowledge of the mechanisms of PB in hypoxic environments will provide important insights into diagnostic and therapeutic decisions for Veterans who suffer from sleep disordered breathing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05037032
Study type Interventional
Source VA Loma Linda Health Care System
Contact Aimee Rodriguez
Phone (909) 583-6818
Email [email protected]
Status Recruiting
Phase Phase 4
Start date August 8, 2021
Completion date August 2023

See also
  Status Clinical Trial Phase
Completed NCT01199042 - Bipap autoSV Advanced in Central Apnea Patients N/A
Recruiting NCT03031626 - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Phase 4
Withdrawn NCT03238937 - Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea N/A
Terminated NCT02820441 - Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance Phase 4
Completed NCT00811668 - Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR N/A
Recruiting NCT03432910 - Application of Forced Breath Technique While CPAP Therapy for Apnea Classification N/A
Withdrawn NCT04630639 - Sparkle Respiratory Effort Validation N/A
Completed NCT01816776 - Respicardia, Inc. Pivotal Trial of the remedē System N/A
Recruiting NCT04926077 - DreamKit Respiratory Effort Signal Validation N/A
Completed NCT01626989 - Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders N/A
Recruiting NCT04399200 - Apnea, Stroke and Incident Cardiovascular Events
Recruiting NCT04671342 - DreamKit Diagnostic Validation N/A
Not yet recruiting NCT01041924 - Dynamic Carbon Dioxide (CO2) Administration for Sleep Apnoea Phase 2
Completed NCT00823134 - Evaluation of ApneaLink Plus Scoring Capabilities N/A
Completed NCT03552133 - Variable Dead Space Rebreathing Device to Treat Sleep Apnea N/A
Completed NCT00720213 - Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device N/A
Recruiting NCT02554487 - Early Sleep Apnea Treatment in Stroke N/A